Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Reactivity of Routine HIV Antibody Tests in Children With Perinatally Acquired HIV-1 in England

Cross-sectional Analysis

Fidler, Katy J., MB BS, MRCPCH, PhD*,†; Foster, Caroline, MB BS, MRCPCH; Lim, Emma J., B.Med.Sci, BMBS, MRCP§; Patel, Amie, BMBS*; Welch, Steven, MSc, MRCP, MRCPCH; Menson, Esse, MB ChB, DPhil, MRCPCH; Klein, Nigel, MB BS, PhD**; Judd, Ali, BSc, MSc, PhD†† for the Collaborative HIV Paediatric Study (CHIPS) Steering Committee

The Pediatric Infectious Disease Journal: February 2019 - Volume 38 - Issue 2 - p 146–148
doi: 10.1097/INF.0000000000002143
HIV Reports

We assessed HIV antibody prevalence in children with perinatally acquired HIV in England. Eighteen percent (10/55) of those starting combination antiretroviral therapy <6 months of age were seronegative at median age 9.1 years and had lower viral load at diagnosis and combination antiretroviral therapy start and fewer viral rebounds, than 45 of 55 seropositives. Implications for patient selection for HIV cure research, and interpretation of routine antibody testing, are discussed.

From the *Brighton and Sussex Medical School

Royal Alexandra Children’s Hospital, Brighton, United Kingdom

The Family Clinic, Imperial College Healthcare NHS Trust, London, United Kingdom

§Great North Children’s Hospital, Newcastle upon Tyne, United Kingdom

Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, United Kingdom

Evelina Hospital, Guy’s and St Thomas’ NHS Foundation Trust

** Institute of Child Health, University College London

†† MRC Clinical Trials Unit at UCL, University College London, London, United Kingdom.

Accepted for publication June 14, 2018.

The Collaborative HIV Paediatric Study has ethical approval from the London Multicentre Research Ethics Committee.

The Collaborative HIV Paediatric Study is funded by the NHS (National Health Service) (London Specialised Commissioning Group) and has received additional support from the PENTA (Paediatric European Network for Treatment of AIDS) Foundation as well as Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen and Roche. Supported by the Medical Research Council program grant MC_UU_12023/26 awarded to the MRC Clinical Trials Unit.

The authors have no conflicts of interest to disclose.

K.F., E.L.J., and N.K. conceived the idea for the study, and K.F. led its design, coordination and article write up. A.J. analyzed the Collaborative HIV Paediatric Study (CHIPS) data and was a major contributor to article preparation. A.P. was involved in initial analysis of seronegative patients. All authors contributed data to the study via CHIPS and/or helped with article preparation. All authors read and approved the final article.

Address for correspondence: Katy Fidler, BSc, MB BS, MRCPCH, PhD, Room 663, Level 6, Royal Alexandra Children’s Hospital, Eastern Road, Brighton, East Sussex BN2 5BE, United Kingdom. E-mail: k.fidler@bsms.ac.uk.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.